GTC BIOTHERAPEUTICS SAYS FRANCE'S LFB TO INVEST $25 MILLION

GTC Biotherapeutics, Inc. and LFB- Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire francais du Fractionnement et des Biotechnologies S.A.) announced that they have entered into a strategic collaboration to develop selected recombinant plasma proteins and monoclonal antibodies using GTC's transgenic production platform. A Joint Steering Committee will agree on product development as well as commercialization plans. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=31737&full=1) (http://allafrica.com/stories/200610010095.html)